Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Athina SpiliopoulouMarco ColomboDarren PlantNisha NairJing CuiMarieke Jh CoenenKatsunori IkariHisashi YamanakaSaedis SaevarsdottirLeonid PadyukovS Louis BridgesRobert P KimberlyYukinori OkadaPiet L Cm van RielGertjan WolbinkIrene E van der Horst-BruinsmaNiek de VriesPaul P TakKoichiro OhmuraHelena CanhãoHenk-Jan GuchelaarTom Wj HuizingaLindsey A CriswellSoumya RaychaudhuriMichael E WeinblattAnthony G WilsonXavier MarietteJohn D IsaacsAnn W MorganCostantino PitzalisAnne BartonPaul McKeigue

Published in: Annals of the rheumatic diseases (2019)

The association with the CD39 trait is difficult to interpret because patients with RA are often prescribed TNFi after failing to respond to methotrexate. The CD39 and CD40 pathways could be relevant for targeting drug therapy.

Keyphrases

rheumatoid arthritis
genome wide
disease activity
dna methylation
mesenchymal stem cells
bone marrow
cancer therapy
drug delivery
ankylosing spondylitis
adverse drug
drug induced